Noticias de Eulerpool Alligator Bioscience

Alligator Bioscience Eulerpool-AFX

Alligator Bioscience Noticias de Acciones

Alligator Bioscience es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Alligator Bioscience.

• 24 de octubre ·

  Yahoo
  Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update
• 9 de octubre ·

  Yahoo
  Alligator Bioscience AB (FRA:7AL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
• 16 de septiembre ·

  Yahoo
  Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
• 13 de septiembre ·

  Yahoo
  Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024
• 11 de julio ·

  Yahoo
  Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update
• 26 de junio ·

  Yahoo
  Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
• 25 de junio ·

  Yahoo
  Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025
• 3 de junio ·

  Yahoo
  Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
• 23 de mayo ·

  Yahoo
  Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
• 1 de abril ·

  Yahoo
  Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences